Welcome to our dedicated page for NeuroSense Therapeutics Ltd. SEC filings (Ticker: NRSNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NeuroSense Therapeutics Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NeuroSense Therapeutics Ltd.'s regulatory disclosures and financial reporting.
NeuroSense Therapeutics reported new long-term survival data from its completed Phase 2b trial of PrimeC in amyotrophic lateral sclerosis (ALS). Patients treated continuously with PrimeC showed an estimated median survival of 36.3 months versus 21.4 months for those initially on placebo, an improvement of over 14 months and about a 70% increase in median survival. A log-rank test showed statistically significant separation between treatment arms (p = 0.0218), and a Cox model associated PrimeC with a 65% reduction in risk of death versus placebo (hazard ratio 0.35; 95% CI: 0.17–0.71; p = 0.0037). The randomized, double-blind, placebo-controlled trial in 68 ALS patients had previously demonstrated slowed disease progression and favorable safety. NeuroSense believes these survival results strengthen the case for advancing PrimeC into pivotal late-stage development.
NeuroSense Therapeutics Ltd. is asking shareholders to approve an amendment to its Articles of Association to increase its registered share capital to 200 million ordinary shares, no par value. The registered share capital is currently 90 million ordinary shares.
As of February 11, 2026, the company had approximately 39 million ordinary shares available for future issuance after accounting for outstanding options, warrants and RSU grants. The board states that the larger share pool is intended to maintain flexibility for strategic financings and other issuances to support continued development of PrimeC, including planned Phase 3 activities.
The proposal will be presented at a Special Meeting of Shareholders scheduled for March 10, 2026, at 4:00 p.m. (Israel time) in Herzliya. Shareholders of record at the close of business on February 17, 2026 are entitled to notice and to vote, and the board unanimously recommends voting in favor.
NeuroSense Therapeutics filed a Form 6-K to highlight a new Australian patent grant for its lead drug candidate PrimeC. The Australian Patent Office granted Patent No. 2022370513, covering compositions combining ciprofloxacin and celecoxib, extending patent protection for PrimeC in Australia through October 2042 and reinforcing a previously granted U.S. patent.
PrimeC is a proprietary fixed-dose, extended-release oral formulation designed to deliver ciprofloxacin and celecoxib in a synchronized way, targeting multiple disease pathways in amyotrophic lateral sclerosis (ALS) and potentially Alzheimer’s disease and other neurodegenerative conditions. NeuroSense describes PrimeC as Phase 3-ready in ALS, following positive Phase 2b results and FDA clearance of a pivotal Phase 3 protocol.
The company frames this Australian patent as part of a broader global intellectual property strategy intended to support the long-term development and potential commercialization of PrimeC across major markets.